Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Metagenomi (MGX) Gains from Sales and Divestitures (2024 - 2025)

Historic Gains from Sales and Divestitures for Metagenomi (MGX) over the last 2 years, with Q3 2025 value amounting to $250280.0.

  • Metagenomi's Gains from Sales and Divestitures fell 3431.8% to $250280.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $250280.0, marking a year-over-year decrease of 3431.8%. This contributed to the annual value of $499148.0 for FY2024, which is N/A changed from last year.
  • Latest data reveals that Metagenomi reported Gains from Sales and Divestitures of $250280.0 as of Q3 2025, which was down 3431.8% from $175160.0 recorded in Q2 2025.
  • Over the past 5 years, Metagenomi's Gains from Sales and Divestitures peaked at $499148.0 during Q4 2024, and registered a low of $94413.0 during Q1 2025.